Your browser doesn't support javascript.

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Home > Búsqueda > ()
Imprimir Exportar

Formato de exportación:


Adicionar mas contactos
| |

Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables.

Ivars Rubio, Alejandra; Yufera, Juan Carlos; de la Morena, Pilar; Fernández Sánchez, Ana; Navarro Manzano, Esther; García Garre, Elisa; García Martinez, Elena; Marín Zafra, Gema; Sánchez Cánovas, Manuel; García Torralba, Esmeralda; Ayala de la Peña, Francisco.
Sci Rep; 9(1): 16979, 2019 11 18.
Artículo en Inglés | MEDLINE | ID: mdl-31740715
The prognostic impact of neutrophil-lymphocyte ratio (NLR) in metastatic breast cancer (MBC) has been previously evaluated in early and metastatic mixed breast cancer cohorts or without considering other relevant prognostic factors. Our aim was to determine whether NLR prognostic and predictive value in MBC was dependent on other clinical variables. We studied a consecutive retrospective cohort of patients with MBC from a single centre, with any type of first line systemic treatment. The association of NLR at diagnosis of metastasis with progression free survival (PFS) and overall survival (OS) was evaluated using Cox univariate and multivariate proportional hazard models. In the full cohort, that included 263 MBC patients, a higher than the median (>2.32) NLR was significantly associated with OS in the univariate analysis (HR 1.36, 95% CI 1.00-1.83), but the association was non-significant (HR 1.12, 95% CI 0.80-1.56) when other clinical covariates (performance status, stage at diagnosis, CNS involvement, visceral disease and visceral crisis) were included in the multivariate analysis. No significant association was observed for PFS. In conclusion, MBC patients with higher baseline NLR had worse overall survival, but the prognostic impact of NLR is likely derived from its association with other relevant clinical prognostic factors.